Human Papillomavirus Molecular Detection with Genotyping
- Communiqué: Screening for Cervical Cancer and Initial Treatment of Patients With Abnormal Results From Papanicolaou Testing
- Featured Topic: Human Papillomavirus (HPV) Molecular Detection with Genotyping
- Featured Topic: Human Papillomavirus (HPV) DNA Detection with Genotyping, High Risk Types by PCR [A Test in Focus]
Published: January 2014
At the end of the Hot Topic presentation, submit your questions on the survey screen that is shown. This is an opportunity for viewers to submit questions to the Hot Topic presenter.
The opportunity to submit questions for this topic is now closed.
The following questions were submitted by viewers and answered by the presenter, Matthew Binnicker, PhD, Director of the Clinical Virology Laboratory in the Division of Clinical Microbiology at Mayo Clinic in Rochester, Minnesota.
Questions are presented as submitted (unedited).
- If a specimen is submitted using the SurePath (SHPV) collection medium outside of the new 14 day stability window will the test be performed or cancelled?
Mayo Medical Laboratories has demonstrated that samples collected into SurePath media are stable for up to 14 days. If a sample is received >14 days past its collection date, the test through Mayo Medical Laboratories will be cancelled.
- For the US poor or countries with limited medical resources, could HPV 16/18 be the stand alone screen? Or the gateway screen to cervical cancer monitoring? Is it cost effective? I feel that PAP testing is subjective and unreliable.
HPV nucleic acid amplification tests (NAAT) are being considered as a first-line screening test. One manufacturer, Roche Diagnostics, has submitted data to the FDA for consideration of the Roche HPV assay as a front-line screening test. If this is approved, it is likely that samples testing positive by a HPV NAAT screening test would be reflexed to cytology for routine examination.